The present disclosure generally relates to implantable medical devices, and particularly relates to measuring anatomical features and determining effectiveness of selected treatments.
The statements in this section merely provide background information related to the present disclosure and may not constitute prior art.
Implantable medical devices (IMD) can be provided for various purposes. For example, IMD's can be provided for pacing or providing other cardiac therapies to a heart of a patient. The pacing can assist in treating arrhythmias or other diagnosed conditions in a patient.
IMD's are generally permanently implanted into a patient. The IMD includes one or more electrodes that are in contact with a portion of the patient. For example, an electrode can be implanted in a right atrium (RA), a right ventricle (RV), and a left ventricle (LV). The various leads can include one or more electrodes that can deliver a current, sense/measure a voltage, measure an impedance, or other appropriate configurations. In addition, the IMD can include a main body that can also include or form an electrode.
An IMD can be implanted into a patient to address various conditions. The IMD case and leads can have various electrodes and other portions to measure various physiological conditions. For example, a selected current can be delivered between two electrodes, either external or internal in the patient, and a voltage can be measured by one or more electrodes of the IMD. A voltage can be measured at two or more locations to determine a relative motion of different electrodes. If the electrodes are in different portions of the heart, a determination can be made of a relative motion or position of the heart or portions of the heart.
Further areas of applicability will become apparent from the description provided herein. It should be understood that the description and specific examples are intended for purposes of illustration only and are not intended to limit the scope of the present disclosure.
The drawings described herein are for illustration purposes only and are not intended to limit the scope of the present disclosure in any way.
The following description is merely exemplary in nature and is not intended to limit the present disclosure, application, or uses. While the subject disclosure includes a detailed description of an implantable medical device for pacing, it is readily appreciated these and similar devices may be applied to an Implantable Cardioverter Defibrillator (ICD).
With reference to
Interconnected with the lead connector block 24 can be a first lead 28a, a second lead 28b, a third lead 28c and a fourth lead 28d. Each of the leads 28a-28d can include respective lead block connection portions 30a-30d. Each of the leads can also include a respective sheath or insulation portion 32a-32d and respective lead tips or tip electrodes 34a-34d. It will be understood that each of the leads 28a-28d can also include multiple electrodes, such as optional ring electrodes 36a-36d. Accordingly, it will be understood that each of the leads 28a-28d can include one or more electrodes, for various purposes, such as sensing, defibrillation, pacing, or other appropriate purposes. Various leads such as the lead 28d, can also include multiple ring electrodes 36d′-36d′″ for use in gathering information regarding the heart, as further discussed herein.
The IMD 20 can be positioned within a patient 40 as illustrated in
The leads can be positioned in any appropriate portion of the anatomy, such as positioning the first lead 28a in a right atrium 46, positioning the second lead 28b in the right ventricle 48, and positioning the third lead 28c in the left ventricle 50. It will be understood that the leads can be implanted at any appropriate location within the heart 42, such as near the tricuspid valve 42a, near a ventricle apex 42b, or any other appropriate specific location. The electrodes 36d′-36d′″ of the lead 28d can be provided solely for gathering and sensing position information. Accordingly, those may be located against a wall of the heart 42. Pacing and defibrillation leads 28a-28c can be positioned generally within at least three regions of the heart 42 for pacing the heart 42, for providing defibrillation into the heart 42, or other appropriate purposes.
An external programmer 60 can be provided to transmit information to, receive information from, and program the IMD 20. The information can be transmitted, or communicated via a wire or substantially wirelessly using telemetry circuitry in the internal electronics system 26, as discussed further herein. The IMD 20 can also sense and store information and transmit it to the external programmer 60 and also receive information or instructions, such as programming, from the external programmer 60, further discussed herein. A processor within the IMD 20 can also be used to alter a therapy based upon sensed information.
According to various embodiments, with reference to
Current can be passed through the patient with the bioimpedance system 80. The bioimpedance system 80 can include a controller and a generating module 81 that drives three pairs of patch electrodes. The patch electrodes can be provided in pairs to form three orthogonal axes, such as an X-axis, a Y-axis and a Z-axis. For example, a first pair of patch electrodes 82a, 82b can inject a current through the patient 40 to form the X-axis. A second pair of patch electrodes 84a and 84b can be positioned on the patient 40 to inject a current form a Y-axis. Finally, two patch electrodes 86a and 86b can be positioned on the patient 40 to inject a current along the Z-axis.
The patch electrodes 82a-86b can be used to inject a current through the patient 40 in any appropriate manner. For example, the patch electrodes used to inject a current can be similar to those disclosed in U.S. Pat. No. 5,697,377, issued on Dec. 16, 1997. Another appropriate system for injecting current is similar to the Localisa™ intracardiac navigation system, sold by Medtronic, Inc. having a place of business in Minneapolis, Minn. It will be understood that the bioimpedance system (EP system) 80 can include various portions that are different from the specifics discussed above, but can generally inject a current within the patient 40 in a similar manner.
Generally, a current of a selected frequency is delivered within the patient 40 through patches 82a-86b. As the current passes through the tissue, a voltage drop occurs as a result of the impedance of the tissue. This voltage can be measured along the corresponding X, Y, and Z axes. For example, muscle tissue, fluid filled organs (such as blood vessels or veins or the heart) are sufficiently conductive to allow for a voltage drop across different areas that can be measured with the electrodes of the leads 28a-28d or even the electrode of the case 22. These voltages can be related to the position of the electrodes based upon knowing the delivered currents. In addition, relative positions of the electrodes can be determined based upon a change in sensed voltage over time.
The patch electrodes 82a-86b can be positioned on the patient 40 using any appropriate mechanism, such as appropriate or tolerated adhesives, or other appropriate means. The patches are generally placed in conductive contact with the skin of the patient 40 to allow for delivery of the current through the internal organs and tissue of the patient 40. The current can generally be about 0.01 mA to about 2.00 mA, including about 1.0 mA. The current is generally injected as an alternating current at about 30 kHz, including about 5 kHz to about 50 kHz.
As discussed above, the IMD 20 and the respective leads 28a-28d are generally positioned within the patient 40. The injection of the current between the patches 82a-86b can generate a voltage that can be measured by the electrodes 34a-36c of the IMD 20 without further invasive procedures. That is, the IMD 20 and leads 28a-28d are already within the patient 40 and no additional internal electrodes are necessary to be introduced into the patient such as by the use of a catheter, etc. As discussed further herein, the measurements of the voltage(s) within the patient 40 can be used to determine positions of the various electrodes that are within the patient 40. The determined position of the electrodes can be used to determine conditions and measurements of the patient 40, such as cardiac dimensions or positions.
With reference to
The P&M module 102 can be interconnected or in communication with a pacing and sensing signal processing (PSS) module 104. It will be understood that more than one PSS module 104, such as PSS modules 104a-104d, can be provided with the IMD 20, such as a distinct PSS module for each of the leads 28a-28d. Each PSS module 104 can receive and send information to and from the P&M module 102 as well as from leads 28a-28d. Further, each of the PSS modules can include the modules and/or circuitry discussed further herein relative to the exemplary PSS module 104. The information from P&M module 102 can direct the PSS module 104 to output a pacing stimulus to a connected lead, 28a-28d. The occurrence of sensing can be communicated to P&M module 102 from PSS module 104. The battery can power the PSS module 104. The PSS module 104 is in communication with the leads 28a-28d that are attached to various portions of the patient 40.
The P&M module 102 can also be in communication with a telemetry module 106 connected to an antenna 108. The telemetry module 106 and the antenna 108 can also receive power from the battery 100, either directly or through the P&M module 102. The telemetry module 106 and the antenna 108 can send and receive information that is processed by the processor or stored in the memory of the P&M module 102. The transmission can be to and from an external source, such as the external programmer 60 or the external bioimpedance system 80. As discussed further herein, the telemetry module 106 can send stored sensed information, processed or stored position information, or other appropriate information.
The P&M module 102 can control timing, detection, sensing, pacing, telemetry, and other functions. Generally, the P&M module 102 can perform functions necessary for pacing functions, diagnostic functions and for follow-up information that is telemetrically transmitted. As is understood, the IMD 20 can be provided for pacing of the heart 42 of the patient 40 in any appropriate and programmed manner. The P&M module 102 can send a signal to the PSS module 104, which can, in turn, send a pacing signal through each of the leads 28a-28c and sense signals from each of the leads 28a-28d.
With additional reference to
Initially, as discussed above, each of the leads can be in communication with a pace module such as module 110. The pace module 110 can combine and transmit a selected pacing stimulus pulse as well as current, of select frequencies to the electrode 28a, based upon instructions or commands from the P&M module 102 and power from the battery 100. Providing a pacing stimulus pulse through the lead 28a is generally known and will not be discussed in detail here.
A sensed signal can also be received through amplifier module 112 to deliver an amplified sensed signal to one or all of the filter or function modules including electrograms 114, myocardial infarction detection 116, sensing for timing and rhythm detection 118, evoked response 120, or impedance/position signal detection 122.
In the electrogram module 114, signals can be processed and sent to the P&M module 102 for telemetry to the external programmer 60. The electrogram signal can also be communicated to the P&M module 102 for analysis and interpretation by the P&M module 102 thus, altering treatment based upon the electrogram module 114.
The pacing and sensing signal processing module exemplified by module 104 can include signal filters for processing information in various spectral portions to isolate electrograms, the electrical signal from electrodes in or on the heart that reflect electrical activation, for example, from lead 28a. The electrogram information can be sent through the telemetry module 106 and antenna 108 to the external programmer 60 for display and/or assisting in augmenting or programming the IMD 20. The electrogram signals can be used to assist in programming the IMD 20.
The electrogram circuitry within module 114 can include various band pass filters to assist in receiving an appropriate signal for processing and/or transmission to the external programmer 60. For example, a band pass of about 1 to 500 Hz can be provided.
The system for analysis of cardiac repolarization, ST segment analysis, such as might be used to detect a myocardial infarct, could utilize circuitry within module 116. A band pass filter of about 0.1 to about 40 Hz can be used to allow for the low frequency constituents necessary for the ST segment to be detected.
Detection of ventricular or atrial depolarizations for timing purposes within the IMD 20 can be accomplished utilizing circuitry within module 118. Such circuitry may contain a bandpass filter of 1 to 30 Hz to detect cardiac activity while avoiding detection of signals due to activation of skeletal muscle, radiation from devices operated by main power at 50 or 60 Hz or recharging of the pacing stimulus output capacitor.
Evoked response detection enabling the IMD 20 to detect whether a pacing stimulus met conditions to capture the heart may be accomplished by circuitry within module 120.
Detection of electrode movement can be accomplished by circuitry within module 122. By injecting a current through lead 28a, from current source 130, an electric field can be established within cardiac tissue or other tissue of interest. Detection and analysis of the resultant sensed voltage due to the injected current can be used to measure and establish movement of cardiac tissue. Analyzing the signals that relate to the frequency of the injected current allows for the determination of the heart's motion 42. If, for example, the injected current is about 30 kHz, then a band pass range of about 25 to about 35 kHz in circuit module 122 could be used to assist in detecting a signal from the lead 28a and determining motion. Analysis of the signal to determine motion can be used by a P&M module 102 to both provide for cardiac pacing and/or defibrillation of the heart for the patient 40. Motion may be used to determine whether an alteration in pacing or defibrillation is required.
The relatively high frequencies used for measuring impedance in the patient 40 can result in relatively high current drain in the IMD 20. Sampling of signals in order to provide a faithful reproduction from current injected in the range of 30 kHz may require sampling intervals such that the sampling frequency is above the Nyquist criteria of twice the fundamental frequency of 30 kHz. That is, sampling of 60 kHz would be required to provide a faithful reproduction. For a long term implantable device, this represents considerable sampling and, therefore, current drain from the battery 100. A technique of undersampling can be used with intentional aliasing of the impedance signal. By undersampling, the signal can be produced that includes substantially the desired and necessary information for transmission, but at a lower current drain.
Each of the processed signals as mentioned above can be telemetrically sent to an external component, such as a bioimpedance system 80 or external programmer 60 by way of the telemetry 106 and antenna 108. In addition, each signal can be used for various purposes, such as a determination of a position of the electrodes, programming or sending information regarding the IMD 20, or of the patient 40. The signals can also be used internally in the IMD 20 to alter the pacing signal by the P&M module 102. It will be further understood that the filters mentioned above can be of any appropriate design, such as an analog or digital design.
With further reference to
Once the IMD 20 including the various electrodes 28a-28d, or any appropriate number of leads is implanted in the patient 40, selected electrodes can be used to determine positions of other selected electrodes. For example, the patch electrodes 82a-86b can be used to inject current that can be sensed with the electrodes of the IMD 20. According to various embodiments, two of the electrodes of the IMD 20 can also or alternatively be used to inject a current from the current source 130 into the patient 40 to generate a voltage to be sensed by another of the electrodes of the IMD 20. For example, the distal electrode 34b of the lead 28b can be a first electrode and the case 22 can be a second electrode.
The case electrode 22 and the distal tip electrode 34b can be used to inject a current through the tissue of the patient 40. Any of the electrodes between the case electrode 22 and the distal tip electrode 34b can be used to measure a voltage. Accordingly, a current injected from the current source 130 and transmitted through the case electrode 22 and the distal tip electrode 34b and can be used to generate a voltage at any of the electrodes between the case electrode 22 and the distal tip electrode 34b. These voltages can be measured and transmitted through the position sensing module 122 for processing by the P&M module 102 and transmission with the telemetry module 106 or for saving in the P&M module 102.
By injecting the current with an implanted electrode within the patient 40, error produced by positioning an electrode patch, such that the patches 82a-86b, on a surface of the patient's 40 skin can be reduced or eliminated. In addition, by using the electrodes implanted as a part of the IMD 20, the IMD 20 can provide a current injection at any time without the need of external or additionally applied current patches of the bioimpedance system 80. For example, the IMD 20 can be programmed to determine a location of a selected electrode 5 times over a selected period. The IMD 20 can, therefore, provide the injected current and measure a voltage at the selected electrode without additional instruments. Accordingly, the electrodes of the IMD 20 can be used to provide substantially efficient measurements of the positions of electrodes implanted as a part of the IMD 20, which correlate to various anatomical features or conditions. As discussed here, the positions of the electrodes of the leads 28a-28d can be measured to determine stroke volume, ejection fraction, dimensions of selected chambers of the heart, and various other hemodynamic indices for the RV, LV, and a combination of RV and LV dimensions. In addition, when electrodes are positioned in appropriate locations, such as on opposite sides of a heart wall, a heart wall thickness or change in thickness can also be measured.
The positions of the electrodes are determined based upon the measured voltages, such as in the Localisa™ intracardiac navigation system sold by Medtronic, Inc. The electrodes of the IMD 20, however, are not directly connected to the external bioimpedance system 80. Because the leads and electrodes positioned within the patient 40 are not directly connected to the bioimpedance system 80, a determination of which axis, X, Y, or Z, current is being injected must be provided. According to various embodiments, a time division multiplex system can be provided to allow for injection of each of the different axes at a substantially different time.
In a time division multiplex system, a current at each of the axes can be injected at a different time within the patient 40 as illustrated in
According to one example, the generator 81 is operable to inject a current at an appropriate frequency into the patient 40 through the patch electrodes 82a-86b. The wave of the generator 81 can include any appropriate frequency and can be selected for various purposes, such as a sampling rate, a power drain, and other appropriate purposes. The generator 81 can also include a switch to allow for switching between selected pairs of the patch electrodes 82a-86b over any period of time, including any appropriate number of cycles.
According to various embodiments, the generator 81 can generate a frequency of about 30 kHz and can switch between each of the patch electrode pairs at any appropriate time interval, such as interval T160, illustrated in
If the frequency of the generator 81 is selected to be 30 kHz and a sample is selected to be measured with an electrode of the IMD 20 every ten cycles, then a sample would be taken approximately every 330 microseconds during each activated period 170. Because there are four distinct time periods T, each activation of the axes and the null 172, time period T occurs every approximately 1.3 milliseconds, which allows about 770 samples per second. Although this would provide a large amount of data relating to the position of the various electrodes, this could also create a large drain on the battery 100 of the IMD 20 and require a large amount of data transmission.
Accordingly, it can be selected to reduce the frequency of the generator 81 and further increase the length of time interval T 160 to reduce the amount of data transmission or battery drain and increase signal to noise ratio in the position detection circuitry 122 of the IMD 20. For example, the frequency of the generator 81 could be about 3 kHz. To allow 100 cycles of the 3 kHz signal requires time period T to be about 33 milliseconds in length, allowing for about 7.5 samples per second. This sampling frequency can be selected to achieve a selected collection of information regarding the heart 42.
Nevertheless, it will be understood that any appropriate frequency can be selected to achieve an appropriate sampling rate of the heart 42 for the position sensing module 122. For example, it can be selected to provide a sample frequency of about ten to fifty samples per second, including about twenty to about sixty samples per second. It will be understood that the sample frequency can be created depending upon a time period T and frequency of the generator 81. For example, a frequency of the generator of about 10 kHz and a time period T of about fifty cycles could greatly increase the sampling frequency of the position sensing module 122.
As discussed above, the position information can be used to determine various characteristics of the heart 42. For example, a high data sample rate can be used to identify substantially accurate and detailed mechanical features of the heart 42. In addition, various disease conditions can be determined, measured based upon the determined positions of the electrodes of the IMD 20, or used in combination with other sensors to detect or assist in detection or fibrillation, chamber volume, and other appropriate details.
In addition, the sequencing as illustrated in
Additional synchronization methods include providing a timing device in both the IMD 20 and the external bioimpedance system 80. The timing devices in the IMD 20 and in the external bioimpedance system 80 can be synchronized at a selected time, such as prior to implantation or with a synchronizing signal. At any time thereafter, the two timing devices are substantially synchronized. Accordingly, when the bioimpedance system 80 powers a selected set of patches, a time signal or determination can also be made. When the impedance is measured by the electrodes of the IMD 20, a time stamp can also be generated. Accordingly, when the measurements are telemetrically sent, the time stamp of the IMD 20 is also sent with the measurements and can be correlated to the time of the injection of the selected axis.
A third synchronization method can use the telemetric system 106 of the IMD 20. A telemetric system 106 can also be provided with the bioimpedance system 80 so that a signal can be sent to the IMD 20 that a selected axis is being powered. Accordingly, the sensed or measured voltage can then be associated with a selected axis of the bioimpedance system 80. This can allow the electrodes associated with the IMD 20 to relate the sensed voltage with an appropriate axis of the bioimpedance system 80.
Other synchronization systems can also be provided. For example, a frequency multiplex system can be used to distinguish the axes of the bioimpedance system 80. For example, each of the three axes, X, Y and Z, can be injected at substantially different frequencies. For example, a current signal along the X axis can be generated at about 31 kHz, the Y axis can be generated at about 32 kHz, and the Z axis can be generated at about 33 kHz. Selected filters can be provided in the position sensing module 122 to distinguish the three frequencies. The band pass filters can allow the selected frequency signal to pass to the P&M module 102.
Sensing a voltage, transmitting the sensed voltage or position information, or other information can cause a power drain from the battery 100. The IMD 20, including the battery 100, is implanted in the patient 40 for a selected period of time. At a particular current drain on the battery 100 a certain service life of the IMD 20 will occur. An average drain can be calculated based on a duty cycle utilization of a system, such as a position sensing module 122. Accordingly, sampling of the voltage detection can be at a selected rate and transmitted with the telemetry system 106 to assure no more than a selected current drain will occur.
As discussed above, it can be selected to demodulate the detected signals from the generated axes to provide a lower frequency signal for transmission from the IMD 20. As discussed above, the injected current generated can be at about 30 kHz. Nevertheless, the demodulation and filtering can provide a signal that is about 100 Hz, such as about 10 to about 500 Hz.
As an example, the frequency of the injected current may be about 10 kHz. For example, the three axes X, Y and Z can each be injected into the patient 40 at a different frequency such as 10.01 kHz, 10.02 kHz, and 10.03 kHz. With reference to
In an attempt to reduce the bandwidth required to transmit the signal of the sensed voltage, the signal can be undersampled at, for example, 100 Hz. As illustrated in
If a transformation, such as a fast Fourier transformation, is performed on the undersampled signal in the frequency domain, the three signal components, those at 10, 20 and 30 Hz above the base line 10 kHz, can be observed, as illustrated in
The transformation can be performed by executing instructions with a selected processor. The processor can be positioned in the external bioimpedance system 80, the external programmer 60, or even as a part of the processor 102. It will be understood that a processor can execute instructions to determine a Fourier transformation of the undersampled signal in the frequency domain to detect the three signal components, or any appropriate number of signal components. It will be understood that the transformation can occur either before or after telemetry of information from the IMD 20, for selected purposes, such as reducing a processing load on the IMD 20 or for other appropriate reasons. In addition, as discussed above, the IMD 20 including the P&M module 102 can alter various programming of the IMD 20, such as a pacing program based upon the determined positions. Accordingly, providing processing of the Fourier transformation in the P&M module 102 can assist in determining position information of the various electrodes associated with the IMD 20.
The sensed voltage can be used to determine positions of the various electrodes of the leads 28a-28d. The voltages can be sensed substantially continuously when a current is injected. The positions of the electrodes can be determined using the external bioimpedance system 80 or an internal bioimpedance system comprising at least two electrodes of the IMD 20. Injecting a current between any two electrodes for measurements of a voltage at another electrode can be used to determine a position of the electrode.
The electrodes of the leads 28a-28c can be positioned for pacing, defibrillation, sensing, and other appropriate purposes. Although any of the leads can be used for determining position information, it will be understood that the leads 28a-28d can include any appropriate number of electrodes to be used substantially only for position determination. For example, the lead 28d can include a tip electrode 34d and any appropriate number of intermediate electrode rings, such as three intermediate electrodes 36d′, 36d″, and 36d′″. The lead 28d can be positioned along or attached to a wall of the heart 42 to provide plural points for position information. These multiple points can provide a substantially detailed view of a particular portion of the heart 42, such as a wall of the heart, when used to sense a position of the multiple electrodes 36d′-36d′″ and 34d. It will be further understood that the multiple lead electrodes can be positioned at any appropriate distance along the lead 28d and can even be passed through more than one chamber of the heart 42 to illustrate relative motion of different portions of the heart 42.
When using the electrodes of the leads 28a-28d, it can be selected to calibrate the position information or the voltages generated relative to the electrodes of the IMD 20. The calibration can include determining the position between any two electrodes having a known position. For example, on the lead 28a, the tip 34a is generally at a fixed position relative to the ring electrode 36a. Accordingly, a determination of a position of each of the two electrodes 34a, 36a and this can be used to calibrate the position system. In addition, it will be understood that when the patch electrodes 82a-86d are positioned on the patient 40, the patch electrodes can be of appropriate sizes to inject the appropriate currents in the patient 40. In addition, the patch electrodes can be sized to provide an increase in a signal-to-noise ratio and decrease distortion generated by injecting a current into the patient 40.
The electrodes of the leads 28a-28d can be used to measure the positions of electrodes associated with each of the leads. The information can be transmitted, either as specific position information or as raw voltage data, to the external programmer 60 or the external bioimpedance system 80 for processing of position information. When the various leads are positioned in the right atrium, right ventricle, and the left ventricle, the leads can generally include electrodes that are substantially fixedly implanted into heart wall tissue in the various chambers. This also positions multiple electrodes within the various chambers so that multiple positions, regarding the various chambers, can be determined using the leads 28a-28d. The information relating to the positions of the leads 28a-28d can be used to identify various anatomical information, such as diseased regions of the heart, stroke volume, volume change and information relating to the various chambers of the heart 42, and other appropriate information. Various examples of information that can be determined using positions of various anatomical features is discussed in U.S. Patent Application Publication No. 2008/0132800 published on Jun. 5, 2008, incorporated herein by reference.
The electrodes positioned in the right ventricle can be used to determine an end diastolic dimension of the right ventricle. The end diastolic dimension can be proportional to a myocardial stretch and chamber volume. As is understood, the end diastolic ventricle or volume is an accepted index of ventricular preload which can be determinant of cardiac performance.
In addition, various leads can be positioned to determine thickness dimensions of a wall of the heart 42. As discussed above, an electrode can be positioned in the right ventricle and in the left ventricle. Accordingly, a thickness of the wall between the two ventricles can be measured instantaneously and over time. Thickening of the wall, generally referred to as hypertrophy, can be associated with hypertension and diastolic dysfunction. A thinning of the wall can be related to ischemia or dilated cardiomyophy. In addition, as discussed above, multiple position measurements can be taken during a single cardiac cycle or over multiple cardiac cycles and can be compared to similar positions within the single cardiac cycle. Therefore, a change in wall thickness can be measured over a cycle of the heart 42 for possible measuring or diagnosis of various cardiac diseases, such as ischemia which can be an indication of regional dyskinesis.
Regardless of the information determinations or calculations based upon the measured positions of the various electrodes, it will be understood that the positions of the various electrodes can be measured using either the external bioimpedance system 80 or an internal bioimpedance system (i.e., using the current source 130 within the IMD 20). Accordingly, a substantially continuous measurement of the positions of the electrodes can be made without requiring the patient 40 to be positioned relative to the external bioimpedance system 80 to determine the positions of the various electrodes. Accordingly, information can be recorded and saved in the P&M module 102 for transmission at a selected time. Additionally, the information saved within the P&M module 102 can be used to determine various pacing and defibrillation treatments of the IMD 20.
The information of the position of the electrodes acquired can be used to alter the programming of the IMD 20. The alteration of the programming of the IMD 20 can be done with the external programmer 60, after analysis of the position information, or done substantially in real time by the IMD 20, including the processor 102. For example, the IMD processor 102 can include instructions that can be executed to alter the programming, including pacing, of the IMD based upon position information of the various electrodes. The positions of electrodes can be determined using the current source 130 or any appropriate current source to determine positions of the electrodes. The IMD 20 can be used to alter the programming, including the pacing, of the IMD 20 without an external programmer. Accordingly, the positions of the electrodes can be used in substantially real time as a part of the treatment provided by the IMD 20.
Further areas of applicability of the present teachings will become apparent from the detailed description provided above. It should be understood that the detailed description and specific examples, while indicating various embodiments, are intended for purposes of illustration only and are not intended to limit the scope of the teachings.
This application is a continuation-in-part of U.S. patent application Ser. No. 11/966,382 filed on Dec. 28, 2007, which application claims the benefit of U.S. Provisional Application No. 60/912,610, filed on Apr. 18, 2007; U.S. Provisional Application No. 60/882,420, filed on Dec. 28, 2006; U.S. Provisional Application No. 60/882,431, filed on Dec. 28, 2006; U.S. Provisional Application No. 60/882,435, filed on Dec. 28, 2006; U.S. Provisional Application No. 60/882,428, filed on Dec. 28, 2006; U.S. Provisional Application No. 60/882,430, filed on Dec. 28, 2006; and U.S. Provisional Application No. 60/882,425, filed on Dec. 28, 2006. The entire disclosures of the above applications are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3837347 | Tower | Sep 1974 | A |
3995623 | Blake et al. | Dec 1976 | A |
4619246 | Molgaard-Nielsen et al. | Oct 1986 | A |
4696304 | Chin | Sep 1987 | A |
4801297 | Mueller | Jan 1989 | A |
5035246 | Heuvelmans et al. | Jul 1991 | A |
5078714 | Katims | Jan 1992 | A |
5099845 | Besz et al. | Mar 1992 | A |
5167239 | Cohen et al. | Dec 1992 | A |
5255680 | Darrow et al. | Oct 1993 | A |
5265622 | Barbere | Nov 1993 | A |
5342295 | Imran | Aug 1994 | A |
5385148 | Lesh et al. | Jan 1995 | A |
5391199 | Ben-Haim | Feb 1995 | A |
5443489 | Ben-Haim | Aug 1995 | A |
5480422 | Ben-Haim | Jan 1996 | A |
5512920 | Gibson | Apr 1996 | A |
5546951 | Ben-Haim | Aug 1996 | A |
5558091 | Acker et al. | Sep 1996 | A |
5568809 | Ben-haim | Oct 1996 | A |
5639276 | Weinstock et al. | Jun 1997 | A |
5697377 | Wittkampf | Dec 1997 | A |
5713946 | Ben-Haim | Feb 1998 | A |
5797849 | Vesely et al. | Aug 1998 | A |
5800407 | Eldor et al. | Sep 1998 | A |
5840025 | Ben-Haim | Nov 1998 | A |
5916193 | Stevens et al. | Jun 1999 | A |
5983126 | Wittkampf | Nov 1999 | A |
6009349 | Mouchawar et al. | Dec 1999 | A |
6088527 | Rybczynski | Jul 2000 | A |
6122552 | Tockman et al. | Sep 2000 | A |
6152946 | Broome et al. | Nov 2000 | A |
6196230 | Hall et al. | Mar 2001 | B1 |
6236886 | Cherepenin et al. | May 2001 | B1 |
6246468 | Dimsdale | Jun 2001 | B1 |
6256121 | Lizotte et al. | Jul 2001 | B1 |
6301498 | Greenberg et al. | Oct 2001 | B1 |
6330356 | Sundareswaran et al. | Dec 2001 | B1 |
6389187 | Greenaway et al. | May 2002 | B1 |
6470205 | Bosselmann et al. | Oct 2002 | B2 |
6546270 | Goldin et al. | Apr 2003 | B1 |
6569160 | Goldin et al. | May 2003 | B1 |
6574498 | Gilboa | Jun 2003 | B1 |
6595989 | Schaer | Jul 2003 | B1 |
6602271 | Adams et al. | Aug 2003 | B2 |
6701176 | Halperin et al. | Mar 2004 | B1 |
6868195 | Fujita et al. | Mar 2005 | B2 |
6888623 | Clements | May 2005 | B2 |
6892091 | Ben-Haim et al. | May 2005 | B1 |
7020522 | Hoijer et al. | Mar 2006 | B1 |
7047073 | Hoijer et al. | May 2006 | B2 |
7189208 | Beatty et al. | Mar 2007 | B1 |
7207989 | Pike, Jr. et al. | Apr 2007 | B2 |
7215430 | Kacyra et al. | May 2007 | B2 |
7263397 | Hauck et al. | Aug 2007 | B2 |
7305121 | Kaufmann et al. | Dec 2007 | B2 |
7421300 | Smits et al. | Sep 2008 | B2 |
7479141 | Kleen et al. | Jan 2009 | B2 |
20010031920 | Kaufman et al. | Oct 2001 | A1 |
20020045810 | Ben-Haim | Apr 2002 | A1 |
20020049375 | Strommer et al. | Apr 2002 | A1 |
20020111662 | Iaizzo et al. | Aug 2002 | A1 |
20030028118 | Dupree et al. | Feb 2003 | A1 |
20030055324 | Wasserman | Mar 2003 | A1 |
20030078494 | Panescu et al. | Apr 2003 | A1 |
20030108853 | Chosack et al. | Jun 2003 | A1 |
20030225434 | Glantz et al. | Dec 2003 | A1 |
20040001075 | Balakrishnan et al. | Jan 2004 | A1 |
20040064159 | Hoijer et al. | Apr 2004 | A1 |
20040070582 | Smith et al. | Apr 2004 | A1 |
20040097805 | Verard et al. | May 2004 | A1 |
20040162599 | Kurth | Aug 2004 | A1 |
20040215298 | Richardson et al. | Oct 2004 | A1 |
20040236395 | Iaizzo et al. | Nov 2004 | A1 |
20040249281 | Olstad | Dec 2004 | A1 |
20040254437 | Hauck et al. | Dec 2004 | A1 |
20050018888 | Zonneveld | Jan 2005 | A1 |
20050119550 | Serra et al. | Jun 2005 | A1 |
20050187432 | Hale et al. | Aug 2005 | A1 |
20050245803 | Glenn, Jr. et al. | Nov 2005 | A1 |
20060013523 | Childlers et al. | Jan 2006 | A1 |
20060058604 | Avinash et al. | Mar 2006 | A1 |
20060117773 | Street et al. | Jun 2006 | A1 |
20060153468 | Solf et al. | Jul 2006 | A1 |
20060173268 | Mullick et al. | Aug 2006 | A1 |
20060200049 | Leo et al. | Sep 2006 | A1 |
20060206157 | Hoijer | Sep 2006 | A1 |
20060229513 | Wakai | Oct 2006 | A1 |
20060229594 | Francischelli et al. | Oct 2006 | A1 |
20060247520 | McGee | Nov 2006 | A1 |
20070016084 | Denault | Jan 2007 | A1 |
20070043413 | Eversull et al. | Feb 2007 | A1 |
20070046661 | Ma et al. | Mar 2007 | A1 |
20070049817 | Preiss et al. | Mar 2007 | A1 |
20070123944 | Zdeblick | May 2007 | A1 |
20070135721 | Zdeblick | Jun 2007 | A1 |
20070135803 | Belson | Jun 2007 | A1 |
20070156019 | Larkin et al. | Jul 2007 | A1 |
20070164900 | Schneider et al. | Jul 2007 | A1 |
20070167801 | Webler et al. | Jul 2007 | A1 |
20070252074 | Ng et al. | Nov 2007 | A1 |
20070270682 | Huang et al. | Nov 2007 | A1 |
20070299351 | Harlev et al. | Dec 2007 | A1 |
20070299352 | Harlev et al. | Dec 2007 | A1 |
20070299353 | Harlev et al. | Dec 2007 | A1 |
20080024493 | Bordoloi et al. | Jan 2008 | A1 |
20080038197 | John et al. | Feb 2008 | A1 |
20080058656 | Costello et al. | Mar 2008 | A1 |
20080071142 | Gattani et al. | Mar 2008 | A1 |
20080118117 | Gauldie et al. | May 2008 | A1 |
20080132800 | Hettrick et al. | Jun 2008 | A1 |
20080183072 | Robertson et al. | Jul 2008 | A1 |
20080207997 | Higgins et al. | Aug 2008 | A1 |
20080243025 | Holmstrom et al. | Oct 2008 | A1 |
20090017430 | Muller-Daniels et al. | Jan 2009 | A1 |
20090063118 | Dachille et al. | Mar 2009 | A1 |
20090103793 | Borland et al. | Apr 2009 | A1 |
20090126575 | Son et al. | May 2009 | A1 |
20090129477 | Yang | May 2009 | A1 |
20090192381 | Brockway et al. | Jul 2009 | A1 |
20090253976 | Harlev et al. | Oct 2009 | A1 |
20090262109 | Markowitz et al. | Oct 2009 | A1 |
20090262979 | Markowitz et al. | Oct 2009 | A1 |
20090262980 | Markowitz et al. | Oct 2009 | A1 |
20090262982 | Markowitz et al. | Oct 2009 | A1 |
20090262992 | Markowitz et al. | Oct 2009 | A1 |
20090264727 | Markowitz et al. | Oct 2009 | A1 |
20090264738 | Markowitz et al. | Oct 2009 | A1 |
20090264739 | Markowitz et al. | Oct 2009 | A1 |
20090264740 | Markowitz et al. | Oct 2009 | A1 |
20090264741 | Markowitz et al. | Oct 2009 | A1 |
20090264742 | Markowitz et al. | Oct 2009 | A1 |
20090264743 | Markowitz et al. | Oct 2009 | A1 |
20090264744 | Markowitz et al. | Oct 2009 | A1 |
20090264745 | Markowitz et al. | Oct 2009 | A1 |
20090264746 | Markowitz et al. | Oct 2009 | A1 |
20090264747 | Markowitz et al. | Oct 2009 | A1 |
20090264748 | Markowitz et al. | Oct 2009 | A1 |
20090264749 | Markowitz et al. | Oct 2009 | A1 |
20090264750 | Markowitz et al. | Oct 2009 | A1 |
20090264751 | Markowitz et al. | Oct 2009 | A1 |
20090264752 | Markowitz et al. | Oct 2009 | A1 |
20090264777 | Markowitz et al. | Oct 2009 | A1 |
20090264778 | Markowitz et al. | Oct 2009 | A1 |
20090265128 | Markowitz et al. | Oct 2009 | A1 |
20090267773 | Markowitz et al. | Oct 2009 | A1 |
20090297001 | Markowitz et al. | Dec 2009 | A1 |
20100030298 | Martens et al. | Feb 2010 | A1 |
20100152571 | Hartmann et al. | Jun 2010 | A1 |
Number | Date | Country |
---|---|---|
363117 | Apr 1990 | EP |
1393674 | Mar 2004 | EP |
1421913 | May 2004 | EP |
WO-02064040 | Aug 2002 | WO |
WO-2005112836 | Dec 2005 | WO |
WO-2006042039 | Apr 2006 | WO |
WO-2006117773 | Nov 2006 | WO |
WO-2007067945 | Jun 2007 | WO |
WO-2007111542 | Oct 2007 | WO |
WO-2007136451 | Nov 2007 | WO |
WO-2008147961 | Dec 2008 | WO |
Number | Date | Country | |
---|---|---|---|
20090093857 A1 | Apr 2009 | US |
Number | Date | Country | |
---|---|---|---|
60912610 | Apr 2007 | US | |
60882420 | Dec 2006 | US | |
60882431 | Dec 2006 | US | |
60882435 | Dec 2006 | US | |
60882428 | Dec 2006 | US | |
60882430 | Dec 2006 | US | |
60882425 | Dec 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11966382 | Dec 2007 | US |
Child | 12183796 | US |